Profile data is unavailable for this security.
About the company
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
- Revenue in USD (TTM)22.05m
- Net income in USD-58.81m
- Incorporated2019
- Employees75.00
- LocationSepterna Inc250 East Grand Avenue, Suite 65SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 338-3533
- Fax+1 (302) 655-5049
- Websitehttps://septerna.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 955.87m | 162.00 | -- | 6.47 | -- | 6.70 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Vir Biotechnology Inc | 16.86m | -499.65m | 962.75m | 408.00 | -- | 1.21 | -- | 57.10 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 970.00m | 106.00 | -- | 2.38 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.20 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Savara Inc | 0.00 | -115.65m | 1.05bn | 59.00 | -- | 9.45 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.05bn | 160.00 | -- | 12.55 | -- | 94.60 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -210.50m | 1.05bn | 100.00 | -- | 3.26 | -- | -- | -3.33 | -3.33 | 0.00 | 4.54 | 0.00 | -- | -- | 0.00 | -45.83 | -- | -50.02 | -- | -- | -- | -- | -- | -- | -43.63 | 0.2021 | -- | -- | -- | -230.31 | -- | -- | -- |
| Septerna Inc | 22.05m | -58.81m | 1.09bn | 75.00 | -- | 2.81 | -- | 49.64 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.11bn | 35.00 | -- | 5.27 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.13bn | 130.00 | -- | 4.52 | -- | 75.19 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.19bn | 156.00 | -- | -- | -- | 846.97 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.21bn | 73.00 | -- | 5.52 | -- | 191.44 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.22bn | 69.00 | -- | 2.38 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Septerna Inc's reporting currency: US Dollar USD
52.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 7.00m | 15.63% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 4.92m | 10.99% |
| BVF Partners LPas of 30 Sep 2025 | 4.02m | 8.97% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 1.42m | 3.17% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.35m | 3.01% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 1.34m | 2.99% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.32m | 2.94% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 1.18m | 2.63% |
| Casdin Capital LLCas of 30 Sep 2025 | 553.27k | 1.24% |
| Geode Capital Management LLCas of 30 Sep 2025 | 545.70k | 1.22% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
